Eph receptor tyrosine kinases and their ephrin ligands have been implicated in neuronal development and neovascularization. Overexpression of ephrin-A1 has been implicated in tumor progression and poor prognosis. However, the mechanisms are not clear. Here, we report a role of the Eph/ephrin system in a cell adhesion mechanism. Clustered erythropoietin-producing hepatocellular receptor A1 (EphA1)/ephrin-A1 complexes on the plasma membrane did not undergo endocytosis, and the cell remained adherent to one another. The cell-cell contacts were maintained in an Eph tyrosine kinase activity-independent manner even in the absence of E-cadherin. EphA1 and ephrin-A1 co-localized in pulmonary endothelial cells, and regulated vascular permeability and metastasis in the lungs. We identified ADAM12 (A disintegrin and metalloproteinase 12) as an EphA1-binding partner by yeast two-hybrid screening and found that ADAM12 enhanced ephrin-A1 cleavage in response to transforming growth factor-b1 in primary tumors. Released soluble ephrin-A1 in the serum deteriorated the EphA1/ephrin-A1-mediated cell adhesion in the lungs in an endocrine manner, causing lung hyperpermeability that facilitated tumor cell entry into the lungs. Depletion of soluble ephrin-A1 by its neutralizing antibody significantly inhibited lung metastasis.
INTRODUCTION
The Eph receptor tyrosine kinases include 14 members in human. There are eight ligands consisting of five glycosylphosphatidylinositol (GPI)-anchored ephrin-As and three membrane-spanning ephrin-Bs. 1 The Eph/ephrin system controls diverse biological functions such as neuronal development, angiogenesis and tumor progression. [2] [3] [4] EphA2 is overexpressed in many tumors. Ephrin-A1 is also highly expressed in some tumors among which EphA2 is downregulated. Given that both EphA2 and ephrin-A1 are expressed in not only tumors but also endothelial cells, their functional involvement in cancer is complex and appears to be dependent on cell type and microenvironment. 5 EphA2 and ephrin-A1 were upregulated in vascular endothelial cells by tumor necrosis factor-a (TNFa) 6 and hypoxia-inducible factor 1a. 7 EphA2 and EphA1, which has the highest homology with EphA2 in the EphA family, and their ligand ephrin-A1 are abundantly expressed in lungs. 8 Ephrin-A1 was originally identified as an immediate early response gene to TNFa and subsequently purified as a soluble factor in tumor conditioned medium. 9 The involvement of EphA2 and ephrin-A1 in cell adhesion has been proposed. 1 For example, both E-and Vascular endothelial (VE)-cadherins promote EphA2/ephrin-A1 interaction by stabilizing cell-cell contacts. Surrounding ephrins may cause tumor confinement, presumably promoting adhesions between tumor cells. However, their mechanistic contribution to metastasis still remains to be uncovered. A clue may come from the finding of soluble forms of ephrin-A1 that potentially function in a non-juxtacrine fashion. 5 We recently reported that EphA1 binds to fibronectin 10 and integrin-linked kinase (ILK), 11 and activation of EphA1 by an artificial ephrin-A1-Fc fusion protein (ephrin-A1-Fc) resulted in cellspreading defects, suggesting a role in cell adhesion. Deterioration of cell spreading in endothelial cells may abolish vascular barrier causing permeability. This idea is supported by the report that ephrin-A1-Fc treatment enhanced EphA2-mediated vascular permeability in lungs. 12 Moreover, in EphA2-knockout (KO) mice, recruitment of leukocytes from blood vessels to the lungs was significantly enhanced by bacterial infections. 13 All of this information suggests a possible involvement of EphA1/ephrin-A1 in the regulation of lung permeability.
ADAMs (A disintegrin and metalloproteinase) are related to snake venom metalloproteinases and matrix metalloproteinases (MMPs). They are structurally classified into two families, the transmembrane form of ADAM and the thrombospodin-like domain-containing ADAM, also known as ADAMTS. Most are overexpressed in various tumors as represented by ADAM12 in glioblastoma multiforme. 14, 15 The human ADAM12 gene encodes two different isoforms, a secreted short variant form termed ADAM12S and a transmembrane form termed ADAM12L. 16 It has been reported that ADAM12 cleaves Heparin-binding EGF-like growth factor (HB-EGF) and modulates its intracellular signaling. 17 ADAM12 has also been implicated in degradation of the extracellular matrixes such as fibronectin. 18 Degradation of extracellular matrixes in tumor microenvironment is essential to cancer cell proliferation and progression. Synthesized inactive forms of ADAM12 may be activated by furin or MMPs by their peptidase activity and, subsequently, the enzymatically activated ADAM12 cleaves growth factors or extracellular matrixes. This process changes growth factor signalings, leading to cancer cell proliferation and progression.
In ephrin-A5 shedding, ADAM10 constitutively binds to EphA3 and cleaves ephrin-A5 expressed in neighboring cells, defined as in trans, and the cleavage is enhanced by binding to ephrin-A5. 19 The ephrin-A2 cleavage by ADAM10 regulates a contactmediated axon repellent. 20 The recognition amino acid 1 sequence by ADAM10 in ephrin-A2 does not exist in ephrin-A1. Therefore, ephrin-A1 may be cleaved by proteinases other than ADAM10.
As a step toward understanding the functions of the Eph/ephrin system in lung metastasis, we herein show the regulation mechanism of the Eph/ephrin system by ADAM12.
RESULTS
The Eph/ephrin system in lung endothelial cells The physiological function of the Eph/ephrin system in lungs is still largely unknown. In order to understand the role of Eph/ ephrin in lungs, we investigated the distribution of EphA1, EphA2 and ephrin-A1 in mouse lungs with each isotype control ( Supplementary Figures S1a-d) . All of them strongly merged with CD31, an endothelial cell marker, on the luminal side of blood vessels (Figures 1a-d) . Both EphA1 and EphA2 co-localized with ephrin-A1 in blood vessels (Figures 1e and f) and capillaries ( Supplementary Figures S1e and f) . We also investigated the distribution of EphA1, EphA2 and ephrin-A1 in lungs that possess metastatic tumors. Taken together with the results of Figures 1a-f, both EphA1 and EphA2 merged with ephrin-A1 in lung endothelial cells (Figures 1g-l) . EphA2-KO mice have significantly less pericyte coverage, suggesting abnormal interactions between endothelial cells and pericytes. 13 Therefore, we examined whether EphA2 and ephrin-A1 co-localized with NG2, a pericyte marker. They failed to co-localize with NG2 ( Supplementary Figures S1g-i) .
The Eph/ephrin system as adhesion molecules Ephrin-A1-Fc has been widely used in Eph/ephrin studies. [21] [22] [23] However, ephrin-A1-Fc does not reflect the physiological functions and topology of ephrin-A1 because ephrin-A1 is a membrane- 24, 25 However, it was not clear whether the Eph-ephrin binding directly serves as adhesion machinery. In order to demonstrate this hypothesis, we used HEK293 cells that express EphA1 and ephrin-A1 at low levels and lack E-cadherin, a key regulator of adherence junction (Supplementary Figure S2) . Ephrin-A1 doubly tagged with YFP and Myc (YFP-ephrin-A1) still bound EphA1 as judged by cell adhesion assays (data not shown). As it is known that ephrin-A1 binds to its receptors in trans, 26 we next examined their subcellular localization using different cells that express either EphA1 or ephrin-A1. Coculture of HEK293 cells stably expressing DsRed-tagged EphA1 (EphA1-DsRed) and YFPephrin-A1 resulted in strongly merged signals at cell boundaries ( Figure 2a, upper panel) . Interestingly, EphA1 and ephrin-A1 did not undergo endocytosis, and the EphA1/ephrin-A1 complex was kept together at the cell boundary even if cultured for longer than 12 h. This phenomenon was also observed in another cell line, E-cadherin-positive MCF-7 cells (Supplementary Figure S3) . Because receptor endocytosis is generally regulated by receptor tyrosine kinase activity, we investigated whether the cell-cell contact is dependent on the EphA1 tyrosine kinase activity by using DsRed-tagged EphA1 kinase dead mutant (K646M, EphA1-KD). We found that EphA1-KD remained in the complex with ephrin-A1 at the cell boundary (Figure 2a, bottom panel) . These data suggest that the Eph/ephrin system can substitute for E-cadherin to mediate cell adhesion. In order to further test this possibility, we performed a cell aggregation assay in the presence of 1 mM ethlylene glycol tetraacetic acid (EGTA), which chelates Ca 2 þ essential for E-cadherin function. We cultured YFP-ephrin-A1/HEK293 and EphA1-GFP/HEK293 individually or in combination. As expected, cell aggregation was enhanced in coculture of EphA1-and ephrin-A1-expressing cells (Figures 2b and c) . We then performed a scratch wound healing assay and found that it was significantly decreased in EphA1-or ephrin-A1-expressing cells (Figures 2d and e) . Thus, the association of EphA1 and ephrin-A1 favored cell adhesion and decreased cell movement. Overexpression of either EphA1 or ephrin-A1 induced cell aggregation and inhibited wound healing (Figures 2b-e) . Moreover, EphA1-KD-GFP also induced cell aggregation and inhibited wound healing as EphA1-wild-type (WT)-GFP did so (Figures 2f and g ). This data suggests that the Eph/ephrin system-mediated cell adhesion is an Eph tyrosine kinase activity-independent function. HEK293 cells endogenously express EphA2 and ephrin-A1 (Supplementary Figure S2) . YFP-ephrin-A1 binds to the endogenous EphA2 and EphA1-GFP binds to the endogenous ephrin-A1. Therefore, individual culture of YFP-ephrin-A1/HEK293 or EphA1-GFP/ HEK293 may induce cell aggregation and inhibit wound healing. In order to demonstrate this hypothesis, EphA2 or ephrin-A1 expression in HEK293, EphA1-GFP/HEK293 and YFP-ephrin-A1/ HEK293 cells was abrogated by an short hairpin RNA (shRNA) against EphA2 or ephrin-A1, and the cells were used for the experiments (Supplementary Figures S4a-d) . Knockdown of EphA2 or ephrin-A1 resulted in significant reduction of cell aggregation (Supplementary Figure S4e) . Moreover, EphA2-Fc treatment for blocking of EphA1-ephrin-A1 binding resulted in significant decrease of cell aggregation (Supplementary Figure S4f) . Knockdown of EphA2 or ephrin-A1 showed much more inhibition in wound healing than cells expressing a non-inhibitory shRNA (control shRNA) or no difference (Supplementary Figure S4g) .
We suppose that ephrin-A1 and EphA1/A2 are necessary and sufficient for cell aggregation. However, for wound healing, in which cell dissociation, migration, and adhesion need to work in concert, they are necessary but their overexpression has rather inhibitory effects.
Phenotypes of EphA1-or EphA2-KO mice As ephrin-A1-Fc stimulation was shown to cause hyperpermeability in mouse lungs, 12 we examined vascular permeability in EphA1-and EphA2-KO mice using Evans Blue (EB). We found a more than twofold increase in lung vascular permeability in both mice compared with B6 mice (Figures 3a and b ). Subsequently, we tested the effect of the Eph/ephrin system on lung recruitment of tumor cells because it has been reported that hyperpermeability is correlated with lung metastasis. 27 Tumor cell recruitment was also enhanced in EphA1-and EphA2-KO mice (Figure 3c ). Ephin-A1 binds to both EphA1 and EphA2. Therefore, it might have been expected that the EphA1 could rescue the function of EphA2 in EphA2-KO mice, and vice versa. However, EphA1 protein level was significantly downregulated in EphA2-KO mouse (Supplementary Figure S5a) , and there was only partial co-localization of EphA2 and CD31 in EphA1-KO mouse lungs (Supplementary Figure S5b) . Figure S8a) . Co-immunoprecipitaion experiments also demonstrated that full-length ADAM12L was precipitated with full-length EphA1 in mammalian cells (Supplementary Figure S8b) . Co-expression of ADAM12L and EphA1 resulted in co-localization at the plasma membrane in HEK293 cells (Supplementary Figure  S8c) , whereas a previous study showed that ADAM12L mostly localized at the Golgi apparatus but not the plasma membrane when ectopically expressed. 28 The Z-stack projection observed by confocal microscopy showed that ADMA12L and EphA1 colocalized at a cell-cell boundary (Supplementary Figure S8d) . In mouse lungs, ADAM12 co-localized with EphA1 in vascular endothelial cells (Supplementary Figure S8e) . Both pull-down and co-immunoprecipitaion assays showed that EphA2 also interacted with ADAM12 in vitro and in vivo ( Supplementary  Figures S8f-h) .
In order to demonstrate ADAM12 enzymatic activity toward ephrin-A1, we used N-terminal GST-and C-terminal FLAG dually tagged recombinant human ephrin-A1 proteins purified from Escherichia coli as a substrate. Although a possible role of MMP-9 and ADAM10 in ephrin-A1 cleavage has been suggested, 19, 29 ADAM12 but not MMP-9 and ADAM10 showed significant enzymatic activity toward ephrin-A1 (Figure 4a ). Although MMP-9 is thought to be a proteinase for ephrin-A1, 29 MMP-9 did not cleave bacterially produced ephrin-A1 in our condition. We supposed that this was because of the difference in the used experimental materials and assay conditions. Every other instance of ADAM-mediated protein ectodomain shedding has been documented to occur only in cis. 30, 31 Recently, however, it was reported that ephrin-A5 cleavage by ADAM10 took place in trans. 19 We tested the effect of two spliced variants of ADAM12 on ephrin-A1 cleavage in trans. Coculture of YFP-ephrin-A1/HEK293 with ADAM12L/HEK293 or ADAM12S/HEK293 resulted in cleavage of YFP-ephrin-A1 (Figure 4b ). The expected molecular sizes of GPI-anchored and cleaved YFP-ephrin-A1 are 52 and 50 kDa, respectively. However, the cleaved YFP-ephrin-A1 ran slightly slower in the anti-Myc immunoprecipitates of the culture medium. Although we do not know the precise reason, it can safely be said that it was actually cleaved and released into the medium.
We also estimated the concentration of the cleaved ephrin-A1 in those culture supernatant by enzyme-linked immunosorbent assay (ELISA) using anti-human ephrin-A1 antibody (Figure 4b ). Ephrin-A1 cleavage was enhanced by coculture with HEK293 cells transiently expressing ADAM12. In ADAM12-untransfected cells, cleaved YFP-ephrin-A1 proteins were detected. This may be caused by another proteinase including MMPs. Subsequently, we tried to demonstrate ephrin-A1 cleavage in trans by ADAM12L in adjacent cells. Coculture of EphA1-DsRed/ADAM12L-expressing cells with YFP-ephrin-A1-expressing cells showed that ephrin-A1 was cleaved by ADAM12L expressed in the opposing cells (Figure 4c ). The Z-stack projection clearly showed that the cleaved ephrin-A1 was endocytosed into an EphA1-DsRed/ADAM12L-expressing cell and formed a ternary complex with EphA1-DsRed and ADAM12L inside the cell (Figures 4d and e) .
Regulation mechanism of the Eph/ephrin system by ADAM12L It was reported that ADAM12 directly bound to transforming growth factor-b receptor II (TGFbRII). 32 Moreover, TGF-b1 regulates the expression level of ADAM12 via the PI3K and MEK signaling pathways. 33 However, the precise physiological functions and relevance of the TGF-b1signaling in the activation of ADAM12 are unknown. According to the previous findings, ADAM12L localizes at the Golgi apparatus, and its translocation to the plasma membrane requires Protein kinase C Epsilon (PKCe) activity. 28 However, our data suggests that EphA1 is involved in the translocation of ADAM12L to the plasma membrane because the ectopically expressed ADAM12 localized at the plasma membrane only when co-expressed with EphA1 ( Supplementary  Figures S8c and d) . In order to identify the relevance of TGF-b1 in regulation of ADAM12 activity, we treated the YFP-ephrin-A1/ EphA1-DsRed cell cocultures with TGF-b1. Interestingly, the Eph/ ephrin complex dissociated, and cleaved YFP-ephrin-A1 was internalized into an EphA1-expressing cell (Figure 5a and Supplementary Figure S9) . Bone morphogenetic protein 4 (BMP-4) treatment which also induces TGFbR signaling had no effect on the Eph/ephrin complex ( Figure 5b ). As the dissociation took place in a short period of time, it may be independent of Smad4-dependent signaling of TGFbR, leading to transcriptional activation of target genes. We next tested whether ephrin-A1 cleavage induced by TGF-b1 is mediated by TGFbR by using SB431542, a TGFbRI inhibitor. The inhibitor treatment significantly reduced phosphorylation of Smad2 and decreased dissociation of the Eph/ephrin complex induced by TGF-b1 treatment (Supplementary Figure S10a, Figure 5b ). In order to clearly see the involvement of TGFbR in ephrin-A1 cleavage by ADAM12, we abrogated the expression of ADAM12 in HEK293 cells using anti-ADAM12 short interfering RNAs (siRNAs) (Supplementary Figure  S10b) and treated the Adam12-deficient cells with TGF-b1. Knockdown of Adam12 efficiently decreased the dissociation of the Eph/ephrin complex at cell boundaries, suggesting a role in ephrin-A1 cleavage upon TGF-b1 treatment (Figure 5b) . Indeed, we found that TGF-b1 treatment in mice significantly increased the level of naturally generated soluble ephrin-A1 in the serum ( Figure 5c ). As expected, TGF-b1 treatment suppressed the inhibition of wound healing by the Eph/ephrin system (Supplementary Figure S10c) . These results demonstrate that the TGF-b1 signaling pathway, presumably non-transcriptional, is correlated with ephrin-A1 cleavage by ADAM12L.
Ephrin-A1 as a therapeutic target for lung metastasis The analysis of human samples from cancer patients showed that ephrin-A1 and/or ADAM12 are overexpressed in various types of malignant tumors. 5, 34 We found that the expression levels of ADAM12 were higher in 3LL than those in LLC ( Supplementary  Figures S11a and b) . We also examined the amount of naturally generated soluble ephrin-A1 in the serum of non-tumor-bearing and 3LL tumor-bearing mice. It was markedly increased in 3LL tumor-bearing mice compared with non-tumor-bearing mice (Figure 6a ). In order to study the function of soluble ephrin-A1 in blood vessels, we treated human umbilical vein endothelial cells (HUVECs) that express EphA2 but not EphA1 with 2 mg/ml nonclustered soluble ephrin-A1-Fc for 30 min. We found that EphA2 and ephrin-A1 were endocytosed into cytosol, and both EphA2 and ephrin-A1 images at cell boundaries that had been merged with that of VE-cadherin completely disappeared (Figure 6b) , and VE-cadherin protein expression was decreased in response to ephrin-A1 stimulation (Figure 6c ). We also found gaps in HUVECs monolayer accompanied by the dissociation of Eph/ephrin (Figure 6d) . A minimum concentration of 0.01 mg/ml ephrin-A1-Fc could induce breakdown of the EphA2/ephrin-A1 complex at the plasma membrane in 30 min (Supplementary Figure S12a) , but even one magnitude less concentration of ephrin-A1 was effective in 6 h (Supplementary Figure S12b) . The concentration is comparable to the serum level of tumor-bearing mice. In order to demonstrate the function of soluble ephrin-A1 in the regulation of lung permeability in mice, B6 mice were intraperitoneally stimulated with ephrin-A1-Fc. The stimulation significantly increased lung permeability (Figure 6e ). We next tested the effect of soluble ephrin-A1 on lung metastasis. Labeled LLC cells were injected to B6 mice tail vein after treatment with ephrin-A1-Fc. Tumor metastasis was significantly enhanced (Figure 7a) , which is consistent with the results of EphA1-and EphA2-KO mice (Figure 3c ). Taken together, we found that soluble ephrin-A1 deteriorated the cell adhesion by the Eph/ephrin complex and facilitates vascular permeability and metastasis. Thus, we hypothesized that neutralization of ephrin-A1 in serum may decrease lung (data not shown). We treated 3LL tumor-bearing mice with antiephrin-A1 antibody three times a week for 3 weeks. The treatment with anti-ephrin-A1 antibody significantly decreased tumor volume and lung metastasis, and the effect was more prominent in metastasis (Figures 7c-e) . In order to confirm whether the effect of the anti-ephrin-A1 antibody therapy is antibody-specific phenomenon, we abrogated the expression of ephrin-A1 in cultured 3LL tumor cells (Supplementary Figure S13a) , named as 3LL-1 cell, by using anti-ephrin-A1 shRNA and subcutaneously inoculated those cells to B6 WT mice. Knockdown of ephrin-A1 in 3LL-1 cells resulted in significant reduction of primary tumor growth (Supplementary Figure S13b) . This phenomenon certainly supports the biological significance of ephrin-A1 expression in tumor cells, but we could not accurately estimate the effect of ephrin-A1 knockdown in 3LL-1 cells on spontaneous lung metastasis, as the metastatic potential of 3LL-1 to lungs of 3LL-1 was lost. The mRNA levels of ephrin-A1 and ADAM12 in 3LL-1 tumors were obviously decreased compared with those in the parental 3LL tumor (Supplementary Figures S13c and d) . Therefore, to address the concern about non-specific effect of an ephrin-A1 neutralizing antibody on the inhibition of lung metastasis, we tried to demonstrate the effect of the depletion of soluble ephrin-A1 on spontaneous metastasis by another strategy. Treatment by EphA2-Fc, which strongly binds to ephrin-A1 with Kd around 1.33 nM, 35 also successfully reduced spontaneous lung metastasis (Figure 7f) . Therefore, we suppose that the effect of anti-ephrin-A1 antibody treatment is due to neutralizing effect of soluble ephrin-A1 and not non-specific effect of anti-ephrin-A1 antibody.
DISCUSSION
Although ephrin-A1 was initially identified as an immediate early response gene to TNFa, whose natural product is either GPI-anchored or secreted, recombinant ephrin-A1-Fc has been widely used for Eph experiments without defining the role of each form of ephrin-A1. We show here that the GPI-anchored form functions as cell adhesion machinery, whereas the secreted form can disrupt cell-cell contacts, resulting in increased endothelial permeability. Both EphA1-and EphA2-KO mice revealed enhanced lung permeability, which may allow extravasation of circulating tumor cells in the lungs. This is seemingly inconsistent with a previous report that lung metastasis by 4T1 breast cancer cells is abrogated in the background of EphA2-KO, where angiogenesis was impaired. 36 However, we propose that vascular permeability enhances tumor cell entry into the lungs but certainly not regrowth. Regrowth requires not only anti-apoptosis as recently demonstrated by vascular cell adhesion molecule 1 (VCAM1) expression in tumor cells 37 but also neo-angiogenesis that is dependent on EphA2. In our spontaneous metastasis experiment with 3LL, the dissemination process may dominate over the regrowth step that might take place in an EphA2-independent manner.
Recently, it was reported that both lung metastasis and primary tumor growth were significantly reduced in ADAM12-KO mice. 38 They suggest that the function of ADAM12 in tumor progression is not due to an increased proteolytic cleavage of EGF ligands. However, the accurate function of ADAM12 in tumor progression has remained to be elucidated. Naturally generated soluble ephrin-A1 was reported to be secreted into culture medium of glioblastoma multiforme that highly express EphA2, ephrin-A1 and ADAM12. 34, 39 The expression level of ADAM12 was markedly elevated in primary tumors and high metastatic tumor in our experiments (Supplementary Figures S11a and b) . Therefore, we suppose that the major site of ADAM12-mediated cleavage of ephrin-A1 is in primary tumors (Figure 7g ). Naturally generated soluble ephrin-A1-containing-conditioned medium showed growth-promoting activity. 40 This may explains the inhibition of primary tumor growth by anti-ephrin-A1 antibody treatment.
We previously reported that tumor-bearing mouse lungs prepare the metastatic soil before tumor cell arrival, and this is mediated by toll-like receptor 4 (TLR4) and its endogenous ligands, S100A8 and SAA3. 41, 42 We also demonstrated that treatments with neutralizing antibodies against vascular endothelial growth factor (VEGF), TNFa or TGF-b1 decreased the expression of S100A8. Both VEGF and TNFa are well-known vascular permeability factors, and TGF-b1 induces ephrin-A1 cleavage by ADAM12. Moreover, ADAM12 expression is dependent on nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) signaling, 43 which could be derived from TLR4 activation by S100A8, SAA3 and TNFa. This suggests that ADAM12 activation might take place also in the lungs. Role of ephrin-A1 in lung metastasis K Ieguchi et al cell boundaries in lung blood vessels, leading to hyperpermeability in response to TGF-b1. Moreover, it has been reported that TGF-b1 induces the expression of MMP-2 and MMP-9. Beauchamp et al. 29 recently reported that MMP-9 also cleaves ephrin-A1 and generates soluble ephrin-A1. Therefore, MMP-9 may cooperate with ADAM12 on the cleavage of GPIanchored ephrin-A1 on the plasma membrane and to facilitate tumor metastasis to lungs.
The mice lacking the EphA2 tyrosine kinase domain showed defective responses to permeability upon soluble ephrin-A1-Fc stimulation in the lungs. 44 Artificially administrated soluble ephrin-A1 to blood stream might be captured by EphA2, lacking (g) A schematic representation of lung metastasis caused by breakdown of the Eph/ ephrin system. ADAM12 cleaves ephrin-A1 at the primary tumor, and naturally generated soluble ephrin-A1 is released to blood. It induces dissociation of the Eph/ephrin complex at cell boundaries in lung endothelial cell. As a result of dissociation of the Eph/ephrin complex, lung vascular permeability is increased, and both intravasation and extravasation of tumor cells are enhanced. Moreover, following ephrin-A1 cleavage in tumor cells, they are free to move and easily migrate to the stroma.
its tyrosine kinase domain. Eph tyrosine kinase activity is required for breakdown of cell-cell contacts mediated by Eph-ephrin binding, although cell-cell contacts mediated by them are in an EphA tyrosine kinase activity independent. Therefore, the data is consistent with our results and support our concepts on positive regulation of lung permeability by soluble ephrin-A1 and EphA1/EphA2. VE-cadherin promotes EphA2/ephrin-A1 interactions by stabilizing cell contacts. 1 Conversely, ephrin-A1-Fc stimulation enhanced lung permeability and resulted in loss of Claudin-5, Zona occludens 1 (ZO-1) and VE-cadherin staining in bovine pulmonary artery endothelial cells (bPAECs). 12 Receptor internalization in response to ephrin-A1 stimulation decreases EphA2 on the cell surface, which in turn mimics the condition of the cell surface in EphA1-and EphA2-KO mice. This suggests that decreased cell surface EphA1 or EphA2 may lead to downregulation of cell adhesion molecules, including Claudin-5, ZO-1, Occludin and VE-cadherin. Given the distinct time course in the downregulation of EphA2 and VE-cadherin after stimulation by ephrin-A1 (Figure 6c ), indirect mechanism are assumed. We conclude that this is one of the reasons why EphA1 could not rescue hyperpermeability caused by KO of EphA2. Naturally generated soluble ephrin-A1 from glioblastoma multiforme induced receptor internalization and downregulation of EphA2.
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EphA2 has also been implicated in the regulation of E-cadherindependent cell-cell adhesion. 45 EphA2 phosphorylated claudin-4, a tight junction molecule, and attenuated association of claudin-4 with ZO-1. 46 These data indicate that loss of EphA2 on cell surface leads to disruption of cell-cell adhesion. In EphA1-KO mouse lung, partial co-localization of EphA2 and CD31 was observed (Supplementary Figure S5b) , whereas EphA2 strongly merged with CD31 in B6 mouse lung. This suggests that EphA1 may be involved in stabilization of EphA2 on cell surface. In any event, further investigation will be required to characterize the interaction between the EphA1 receptor and cell adhesion molecules.
We focused on the Eph/ephrin system in lung blood vessels and characterized the regulation mechanism. Anti-ephrin-A1 therapy successfully reduced lung metastasis in mice. Therefore, these findings may indicate a new pathway toward the development of drugs for lung metastasis.
MATERIALS AND METHODS Materials
Antibodies against FLAG and GFP tag were purchased from Wako (Osaka, Japan). An antibody against Myc tag and SB431542 were purchased from Sigma-Aldrich (St Louis, MO, USA). Recombinant ephrin-A1-Fc, EphA1-Fc, EphA2-Fc, TGF-b1, MMP-9 and ADAM10 were purchased from R&D Systems (Minneapolis, MA, USA). BMP-4 was purchased from Peprotech (Rocky Hill, NJ, USA). Human recombinant ADAM12 was purchased from Enzo Life Science (Farmingdale, NY, USA). A neutralizing antibody against ephrin-A1 (AF702, Master Lot No. BW02) was purchased from R&D systems.
Plasmids GFP-and FLAG-tagged human EphA1 were prepared as previously described. 10 DsRed-tagged human EphA1-WT (EphA1-DsRed) and kinase dead mutant (EphA1-KD) were subcloned into pDsRed-monomer N1 (Takara Bio, Shiga, Japan) using EcoRI and XhoI sites. Human YFP-tagged ephrin-A1 was constructed as previously described. 20 Human ADAM12 plasmid vectors were kindly provided by Dr Ulla Wewer.
28 N-terminal GSTand C-terminal FLAG-tagged ephrin-A1 (19-205aa) was subcloned into pGEX6P-1 (GE Healthcare, Uppsala, Sweden) using EcoRI and XhoI sites.
Cell culture
Human embryonic kidney 293 cells were cultivated in Dulbecco's modified Eagle's medium (Sigma-Aldrich) supplemented with 10% (v/v) fetal bovine serum, 100 IU/ml penicillin and 100 mg/ml streptomycin. HUVEC were obtained from (Takara) and cultivated in human endothelial-SFM basal growth medium (Life Technologies) supplemented with 10% (v/v) horse serum, 100 IU/ml penicillin, 100 mg/ml streptomycin and endothelial cell growth supplement (Millipore, Billerica, MA, USA). 3LL-1 was originally established from 3LL tumor by A Deguchi in our lab.
Establishment of stable cell lines
Plasmids were introduced into HEK293 cells using SuperFect (Qiagen, Hilden, Germany) according to the manufacturer's instructions. HEK293 cells expressing EphA1-WT-GFP, EphA1-KD-GFP, YFP-ephrin-A1, EphA1-WTDsRed or EphA1-KD-DsRed were cultured in the presence of 1200 mg/ml G418 (Wako) for 14 days before isolation of GFP-, YFP-or DsRed-positive cells by a cell sorter (Epics Altra, Beckman Coulter, Miami, FL, USA).
Animal study C57BL/6J mice were purchased from Clea (Tokyo, Japan). EphA1-and EphA2KO mice were generated as previously described. 47, 48 The mice were used for experiments at 10-12 weeks old. The permeability assay was described previously. 27 For the lung metastasis assay, LLC cells (1 Â 10 5 cells/mouse) were labeled with fluorescent dye (PKH-26, Sigma-Aldrich) and intravenously injected to mice. After 16 h, the lungs were analyzed by a flow cytometer (Cytomics FC500, Beckman Coulter). For anti-ephrin-A1 therapy, B6 mice were subcutaneously inoculated with a piece of 1 mm 3 3LL tumor and injected with 10 mg of anti-ephrin-A1 antibody into the tail veins from 3 days after tumor inoculation until the 14th day, three times a week. Subsequently, the mice were injected with 20 mg of the antibody three times a week until they were killed. Tumor volumes were measured with a standard caliper and calculated as (length Â width 2 )/2, with the length and width defined as the long and short axes, respectively. All procedures performed with the mice were approved by the Animal Research Committee of Tokyo Women's Medical University.
Immunofluorescence microscopy
Immunofluorescence stainings of cultured cells, lung or tumor frozen sections were performed as described previously. 49 Briefly, dillution of antibodies are as follows: EphA1 (1:100, Abcam, Cambridge, UK), EphA2 Cell aggregation assay HEK293 cells treated with 20 mM EDTA/PBS were washed with HBSS without Mg 2 þ and Ca 2 þ , and resuspended in HBSS containing DNaseI. The cells were passed five times through a 30 G needle to make a singlecell suspension. The cells (1 Â 10 6 ) were incubated for 1 h at room temperature with gentle agitation followed by incubation for an additional 3 h in a CO 2 incubator. Cell aggregation was defined as a cell mass gathering 4 and over. The surface area of cell aggregations was estimated by NIH ImageJ. A hematocytometer (1 Â 10 À 2 mm 2 ) was used for the control area.
Protein expression and purification of ephrin-A1
GST-fused ephrin-A1-FLAG was prepared as previously described. 50 Briefly, E. coli cells harboring pGEX6P-1-ephrin-A1-FLAG were induced with 0.1 mM isopropyl b-D-thiogalactopyranoside for 2 h at 26 1C. Harvested cells were suspended in Tris-based buffer (50 mM Tris-HCl (pH 7.4), 100 mM NaCl, 1 mM EDTA and 1.5 mg/ml aprotinin), sonicated and centrifuged at 100 000 g for 30 min at 4 1C. GST-ephrin-A1-FLAG was purified by glutathione affinity chromatography from bacterial extracts as described in the manufacturer's instructions (GE Healthcare). In order to remove endotoxin, glutathioneagarose column was extensively washed with 1% Triton X-114 in PBS before eluting proteins with 5 mM glutathione.
ELISA for soluble ephrin-A1 EphA2-Fc (200 ng/well) was immobilized on an ELISA plate (Fisher Thermo Scientific, Waltham, MA, USA), and then the wells were blocked with protein-free blocking buffer (Fisher) for 30 min. Twenty microliters of mouse serum was diluted in 30 ml of PBS and incubated in the wells for 1 h. The wells were incubated with biotinylated anti-ephrin-A1 antibody (for mouse ephrin-A1 (R&D Systems, AF702, 1:1000), for human ephrin-A1 (Santa Cruz, sc-911, 1:1000)) for 1 h followed by incubation with HRPconjugated streptavidin (1:2000) and washed with 200 ml of 0.05% Triton X-100/PBS five times followed by incubation with OptEIA (BD Biosciences).
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The wells were measured by a microplate reader (Multiskan G0, Fisher Thermo Scientific) at 450 and 570 nm. Dilution series of mouse or human ephrin-A1-Fc (50 ng-3 pg) was used as the reference to calculate the level of ephrin-A1 in serum or conditioned medium.
Statistical analysis
Data are expressed as means ± s.d. Comparisons between two groups were performed with the two-tailed, paired Student's t-test. In all experiments, Po0.05 was considered statistically significant. Data were also analyzed by Bonferroni's multiple comparison test in all cases to determine pairwise significance using GraphPad Prism software 5 (Graphpad Software Inc., La Jolla, CA, USA).
